Last reviewed · How we verify
Full Dose MDMA
At a glance
| Generic name | Full Dose MDMA |
|---|---|
| Sponsor | VA Office of Research and Development |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- MDMA-Assisted Therapy for Veterans With PTSD and Alcohol Use Disorder (PHASE2, PHASE3)
- Randomized, Double-blind, Placebo-Controlled Pilot Study of MDMA-assisted Therapy for PTSD (PHASE2)
- Study Comparing Three Doses of MDMA Along With Therapy in Veterans With Posttraumatic Stress Disorder (PHASE2)
- Randomized Placebo-controlled Study of MDMA-assisted Therapy in People With PTSD - Israel (PHASE2)
- Dose-Response Study of MDMA-assisted Psychotherapy in People With PTSD (PHASE2)
- Study of 3,4-Methylenedioxymethamphetamine-assisted Psychotherapy in People With Posttraumatic Stress Disorder (PHASE2)
- MDMA-assisted Therapy in People With Anxiety Related to Advanced Stage Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Full Dose MDMA CI brief — competitive landscape report
- Full Dose MDMA updates RSS · CI watch RSS
- VA Office of Research and Development portfolio CI